Xenetic Biosciences to Hold Business Update Conference Call January 20th
Xenetic Biosciences Completes Enrollment of Second Cohort in Phase 2a Study with ErepoXen® for Anemia; Hemoglobin Levels Rise into Therapeutic Range over Time
Xenetic Biosciences CEO Delivers “2014 – The Year in Review” Update to Investors and Stakeholders
Xenetic Biosciences Announces OncoHist™ Preclinical Data to be Featured in a Poster Presentation at the American Society of Hematology Annual Meeting
Xenetic Biosciences Partner Completes Dosing of Second Cohort in Phase 2a Study of ErepoXen® in Patients with Chronic Kidney Disease on Dialysis
Xenetic Biosciences Provides Update on Substantial Patent Grants and Allowances in U.S. and Worldwide
Xenetic Biosciences Partner Completes First Patient Cohort in Phase 2 Study with MyeloXen™ for Multiple Sclerosis
Xenetic Biosciences to Hold Business Update Conference Call September 23 at 6:00 a.m. Eastern Time
Xenetic Biosciences Announces Ongoing Safety and Efficacy Data From Phase 2 Trial of ErepoXen(R)
